Y
Yolonda L. Colson
Researcher at Harvard University
Publications - 208
Citations - 9193
Yolonda L. Colson is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 47, co-authored 186 publications receiving 7751 citations. Previous affiliations of Yolonda L. Colson include Brigham and Women's Hospital & University of Pittsburgh.
Papers
More filters
Journal Article
Antiviral Cytotoxic Activity Across a Species Barrier in Mixed Xenogeneic Chimeras: Functional Restriction to Host MHC
Yolonda L. Colson,Ralph A. Tripp,Peter C. Doherty,Sherry M. Wren,Michael Neipp,Ashraf Y. Abou El-Ezz,Suzanne T. Ildstad +6 more
TL;DR: The current study demonstrates that mouse and rat T lymphocytes that have developed in xenogeneic chimeras are restricted to Ag presentation by mouse, but not rat, APC, and results in functional immunocompetence with generation of antiviral cytotoxic activity in vivo, within and across species barriers.
Journal ArticleDOI
Intraoperative seed placement for thoracic malignancy-A review of technique, indications, and published literature
Alexandra J. Stewart,Subhakar Mutyala,Caroline L. Holloway,Yolonda L. Colson,Phillip M. Devlin +4 more
TL;DR: This technique has the potential to improve local control with optimal sparing of normal tissue owing to its highly conformal radiotherapy delivery and the published experience of brachytherapy implants within the thorax.
Journal ArticleDOI
Ease of synthesis, controllable sizes, and in vivo large-animal-lymph migration of polymeric nanoparticles.
Kimberly Ann V. Zubris,Onkar V. Khullar,Aaron P. Griset,Summer L. Gibbs-Strauss,John V. Frangioni,Yolonda L. Colson,Mark W. Grinstaff +6 more
TL;DR: These investigations further support the development of new materials and clinical approaches to treat cancer including identification of nodal disease, characterization of the extent of disease, and establishment of treatment regimes.
Journal ArticleDOI
Facilitating cells : Novel promoters of stem cell alloengraftment and donor-specific transplantation tolerance in the absence of GVHD
TL;DR: The promotion of durable stem cell engraftment in MHC disparate recipients, GVHD inhibition and tolerance induction by the FC suggests that future therapies in hematopoietic cell transplantation andolerance induction for solid organ transplants may be significantly improved through the application of FC transplantation.
Journal ArticleDOI
Associations of HLA-A, B, DR antigens with primary disease in cardiac allograft recipients.
TL;DR: The association of HLA antigens A, B and DR with atherosclerotic coronary artery disease, dilated cardiomyopathy and myocarditis in a series of patients who have undergone orthotopic cardiac transplantation is reported on.